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Inhibitor of DNA binding (Id2) is a helix-loop-helix (HLH) transcription factor that participates in cell diﬀerentiation and
proliferation. Id2 has been linked to the development of cardiovascular diseases since thiazolidinediones, antidiabetic agents and
peroxisomeproliferator-activatedreceptor(PPAR)gammaagonists,havebeenreportedtodiminishId2expressioninhumancells.
We hypothesized that PPARα activators may also alter Id2 expression. Fenoﬁbrate diminished hepatic Id2 expression in both late
pregnant and unmated rats. In 24 hour fasted rats, Id2 expression was decreased under conditions known to activate PPARα.I n
order to determine whether the ﬁbrate eﬀects were mediated by PPARα, wild-type mice and PPARα-null mice were treated with
Wy-14,643 (WY). WY reduced Id2 expression in wild-type mice without an eﬀect in PPARα-null mice. In contrast, fenoﬁbrate
induced Id2 expression after 24 hours of treatment in human hepatocarcinoma cells (HepG2). MK-886, a PPARα antagonist, did
not block fenoﬁbrate-induced activation of Id2 expression, suggesting a PPARα-independent eﬀect was involved. These ﬁndings
conﬁrm that Id2 is a gene responsive to PPARα agonists. Like other genes (apolipoprotein A-I, apolipoprotein A-V), the opposite
directional transcriptional eﬀect in rodents and a human cell line further emphasizes that PPARα agonists have diﬀerent eﬀects in
rodents and humans.
1.Introduction
Fibrates have been eﬀectively used to reduce plasma triglyc-
eride levels under conditions of hypertriglyceridemia [1].
The molecular basis for the action of ﬁbrates on lipid
metabolism involves the activation of transcription fac-
tors, known as peroxisome proliferator-activated receptors
(PPARs), principally the PPARα subtype expressed in liver
([2], for a review). Fibrates decrease the gene expression
of apolipoprotein C-III, and increase the expression of
fatty acid-catabolizing enzymes like acyl-coenzyme A oxi-
dase [3]a n d1 7 β-hydroxysteroid dehydrogenase (17β-HSD)
type IV [4] in rodent liver. Fibrates also display other
eﬀects, not directly related to the lowering of plasma lipids,
including the modulation of immune and inﬂammatory
responses. Thus, these drugs downregulate acute-phase
protein expression, such as ﬁbrinogen, C-reactive protein,
and α2-macroglobulin [5–7].
PPARs also play an important role in glucose homeosta-
sis. PPARα agonists, by upregulating fatty acid oxidation and
ketone body production, are able to spare glucose. Several
studies have indicated a beneﬁcial eﬀect of PPARα activation
on insulin sensitivity [8, 9]. Thus, hyperinsulinemia and2 PPAR Research
hyperglycemia observed in mice subjected to a high-fat
diet or in genetic insulin-resistant rodents [8] were sharply
reduced by treatment with ﬁbrates. The antidiabetic thiazo-
lidinediones (TZD) drugs which are ligands of the PPARγ
subtype, are prescribed for regulating glucose metabolism
because they lower blood glucose by enhancing peripheral
insulin sensitivity [10].
It has been shown that the levels of Id2, a member of
the helix-loop-helix (HLH) transcriptional repressor protein
family which includes Id1-4 [11, 12], are reduced in aortic
smooth muscle cells by treatment with TZD suggesting
that Id2 might play a role in their antidiabetic eﬀects [10].
Furthermore, since glucose increases Id2 protein levels, Id2
could contribute to changes in cellular function that occur
in insulin-resistant and diabetic states [13]. Interestingly,
Id2 is upregulated in muscle, fat, and liver of obese ob/ob
mice [14]. Park et al. [15] have demonstrated that Id2
is a transcriptional modiﬁer of PPARγ expression and
adipogenesis and found that Id2 expression is elevated in
adipose tissues of diet-induced obese mice and humans
leading to the hypothesis of a role for Id2 in obesity and
insulin resistance. Furthermore, Id2 nullizygous mice show
altered expression of genes involved in lipid metabolism
which could be related to reduced lipid storage in liver
and white adipose tissue [16]. These authors also found
that genes involved in glucose homeostasis exhibited altered
expression in Id2-null mice.
Id proteins participate in development, cell cycle con-
trol, diﬀerentiation, and tumorigenesis [17]. Id2 protein
heterodimerizes with E proteins, a subset of basic HLH
(bHLH) transcription factors [18] and sterol regulatory
element-binding protein-1c (SREBP)-1c [19], but because
Id2 lacks a DNA binding domain, Id2 acts as a domi-
nant negative regulator of these transcription factors [11].
Additionally, Id2 is able to regulate the function of HLH
transcription factors indirectly by sequestering E proteins
[18].
Changes in lipid metabolism and insulin resistance
during late pregnancy are comparable to that normally seen
in type 2 diabetic patients, in which the use of ﬁbrates
is recommended [20]. For that reason, late pregnancy has
been previously used by our group [2, 21–24] and other
authors [25–28] to study the eﬀect of PPAR agonists. We
haveusedtheseexperimentalsettingstodiscovernewPPARα
target genes in rodents [7]. Thus, we have used late-gestation
rats to study the eﬀect of ﬁbrates in hepatic Id2 mRNA
expression. In addition, since free fatty acids (FFA) are
known to act as PPARα activators and fasting increases
circulating FFA [29–31], the role of FFA on the Id2 mRNA
expression was investigated in fasted rats. Furthermore, in
order to determine whether the eﬀect of ﬁbrates on Id2 gene
expression is mediated by PPARα, wild-type and PPARα-
null mice were used. Finally, in order to study whether the
eﬀect of ﬁbrates on Id2 gene expression is species-speciﬁc,
the human hepatocarcinoma cell line (HepG2) was used as a
model system.
2.MaterialsandMethods
2.1. Animals, Drug Administration, and Collection of
the Samples
Study I. Female Sprague-Dawley rats weighing 180–210g
were fed ad libitum standard rat chow (B&K Universal,
Barcelona, Spain) and housed under controlled light and
temperature conditions (12h light-dark cycle; 22±1◦C).
The experimental protocol was approved by the Animal
Research Committee of the University San Pablo-CEU,
Madrid, Spain. Half the animals were mated, and day
0 of pregnancy was determined by the appearance of
spermatozoids in vaginal smears, whereas the remaining half
were kept virgin. From day 16 of gestation, rats were given by
oral gavage two daily doses of 0, 100 or 200mg of fenoﬁbrate
(Sigma-Aldrich, St Louis, MO, USA)/kg of body weight, one
at 8.00h and the other at 18.00h, suspended in 2% Tween-
80 or Tween-80 alone. On the morning of the 20th day of
pregnancy (after 4 days of treatment), corresponding to 14h
after receiving the last treatment, rats were decapitated and
blood collected using tubes containing Na2-EDTA. Liver was
immediately removed, placed in liquid nitrogen and kept at
−80◦C until analysis. Virgin rats received the same treatment
and were studied in parallel. There were 5-6 animals per
group.
Study II. Female Sprague-Dawley rats weighing 180–210g
were mated, and half the animals were subjected to fasting
for 24h at day 19 of pregnancy. At day 20 of pregnancy,
bloodandliverwerecollectedasbefore.Plasmaaliquotswere
kept at −20◦C until processing for the analysis of FFA by
enzymatic commercial kit (Wako Chemicals GmbH, Neuss,
Germany).
Study III. Male SV129 wild-type mice were purchased from
Taconic (Germantown, NY, USA), and male SV129 PPARα-
null mice [32] were a kind gift from Frank Gonzalez
(National Cancer Institute, Bethesda, MD, USA). Control
and treated mice (n = 2–5) were provided NIH-07
rodent chow (Ziegler Brothers, Gardner, PA, USA) and
water ad libitum. This study was conducted under federal
guidelines for the use and care of laboratory animals
and was approved by the Chemical Industry Institute of
Toxicology Institutional Animal Care and Use Committee
(NC, USA). Lighting was on a 12 hr light/dark cycle. Mice
were fed diet supplemented with either Wy-14,643 (WY)
(ChemSyn Science Laboratories, Lenexa, KS, USA) (0.1%)
or di-(2-ethylhexyl)phthalate (DEHP) (Aldrich Chemical,
Milwaukee, WI, USA) (0.6%), or a control diet for 3 weeks.
WY and DEHP were selected because of their diﬀerent
structural properties and uses. DEHP is considered a weak
PPAR activator compared to WY. At the designated time
after treatment, animals were anesthetized by pentobarbital
injection and killed by exsanguination. Livers were removed,
rinsed with isotonic saline, snap-frozen in liquid nitrogen,
a n ds t o r e da t−80◦C until analysis.PPAR Research 3
Study IV. Human hepatocarcinoma cells (HepG2) were
obtained from American Type Culture Collection (HB-
8065) (Manassas, VA, USA) and cultured in EMEM media,
supplemented with 1% glutamine, 1% nonessential amino
acids, 3% antibiotics (100U/mL penicillin and 100μL/mL
streptomycin), and 10% fetal bovine serum. All cells were
grown in a 5% CO2-humidiﬁed atmosphere at 37◦C. After
conﬂuence, cells were cultured in serum-free medium (with
0.1% BSA) for 24 hours and diﬀerent concentrations of
fenoﬁbrate (0, 10, 50, and 100μM) in DMSO were added.
After diﬀerent times of incubation (2, 6, and 24 hours),
media was collected and cells were washed with ice-cold
PBS and removed with a cell scraper. After centrifugation,
cell pellets were frozen and used for RNA extraction. In
some cases, cells were preincubated for 30 minutes [33]
with the PPARα antagonist MK-886 (Enzo Life Sciences
Inc., Farmingdale, NY, USA) (10μM) dissolved into DMSO.
DMSO concentration in culture medium did not exceed
0.1%. An additional experiment was carried out in the same
conditions as described above but the cells were instead
cultured in serum-free medium for 36 hours, and then
treated with the drugs.
2.2. Total RNA Preparation and Analysis
Studies I and II. Rat total hepatic RNA was isolated by
a modiﬁcation of the guanidium isothiocyanate method
using Ultraspec RNA according to the manufacturer’s
instructions (Biotecx Labs, Houston, USA). Total RNA
concentration was determined by absorbance measurement
at 260nm. The 260/280 absorption ratio of all samples
was between 1.8 and 2.0. Total RNA-genomic DNA-free
samples were used to analyse the expression of Id2 gene
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
asendogenouscontrol,bysemiquantitativeRT-PCR,accord-
ing to previously described protocols [7, 24]. Brieﬂy, total
RNA (2.5μg) was digested with 5 U RNase free-DNaseI
(Roche, USA) for 20 minutes at 37◦Ct or e m o v et r a c e s
of genomic DNA. The DNase was inactivated at 64◦Cf o r
10 minutes and cDNA was synthesized from total RNA by
oligo(dT)-primed reverse transcription with Superscript II
(Invitrogen, Life Technologies Ltd., Paisley, UK), according
to the manufacturer’s instructions. PCRs were performed in
a2 5 μL reaction mix containing 20pmol of both forward
and reverse primer, 10mmol/L of each deoxyribonucleoside
triphosphate, appropriate dilutions of the cDNA stock,
2.5μL of PCR 10X buﬀer, and Accu Taq-polymerase (Sigma-
Aldrich,StLouis,MO,USA).Thesenseandantisenseprimer
sequences were 5 -GAAAAACAGCCTGTCGGACCA-3  and
5 -CCAGGGCGATCTGCAGGT-3  for Id2 (205bp prod-
uct); and 5 -ACCACAGTCCATGCCATCAC-3  and 5 -
TCCACCACCCTGTTGCTGT-3  for GAPDH (450bp prod-
uct) [34, 35].
AllreactionswereperformedinaPTC-100Thermocycler
(MJ Research, USA) in which samples underwent a 3 min
initial denaturing step, followed by 35 cycles of 45s to
1min at 94 ◦C, 45s at the annealing temperature of 65◦C
for Id2 and 57◦C for GAPDH, and a primer extension step
at 72◦C for 45s to 1min. The ﬁnal extension step was
10min at 72◦C. The PCR products were analysed by agarose
gel electrophoresis and DNA was visualized by ethidium
bromide staining and using a UV-light box. Band intensity
was determined by quantitative scanning densitometry (GS-
700 Imaging Densitometer, BioRad, Hercules, CA, USA).
To determine the linear range of the PCR, dilutions of the
cDNA preparations were previously used for each gene and
experimental group of rats. Results were normalized to the
c o n t r o lg e n e( G A P D H ) .
Study III. Total RNA was isolated from mouse livers by
a modiﬁcation of the guanidinium isothiocyanate method
using RNAzol according to manufacturer’s instructions (Tel-
Test, Friendswood, TX, USA). Twenty μg of denatured total
RNA was separated on 1.2% agarose gels and transferred to
nylonmembranesin20xSSC.TheDNAprobesforNorthern
blot analysis were labeled with [α-32P]dCTP using the
random primer DNA labelling kit provided by Amersham.
Probes used were a rat L-bifunctional enzyme (Ehhadh)
cDNA fragment, the complete cDNA of rat 17β-HSD type
IV [4] and the PCR products generated as indicated above in
the studies I and II, and using rat cDNA as a template. The
probes were sequenced (ABI PRISM 377 Perkin Elmer DNA
sequencer), and the sequences obtained were compared to
Gene Bank sequences to conﬁrm the accuracy of the probes
used.Blotswereprehybridizedat42◦Cfor2handhybridized
overnight at the same temperature. Washing conditions were
0.1x SSC, 0.1% SDS at 53◦C for 15min three times, and
membranes were exposed to appropriate screens (Imaging
Screen K, BioRad) at 4◦C from 1h to three days and the
images analyzed (Personal Molecular Imager FX, BioRad).
Filters were stripped of label at 75–80◦C for 1h with 0.1x
SSC, 0.5% SDS, 0.1% tetrasodium pyrophosphate and then
rehybridized.
Study IV. Total RNA was isolated from HepG2 cell pellets
by QIAcube automated protocol using spin-column kit
(RNeasy Mini Kit, QIAGEN, Hilden, Germany). Total RNA
concentration was determined by absorbance measurement
at 260nm. The 260/280 absorption ratio of all samples was
between 1.8 and 2.0. Total RNA-genomic DNA-free samples
were used to analyse the expression of Id2 and β-actin
as a control, by reverse transcription and quantitative
real time PCR (qPCR) assays, according to the following
protocol: cDNA was synthesized from 1μgt o t a lR N A
by Transcriptor high ﬁdelity cDNA synthesis kit (Roche,
Mannheim, Germany), according to the manufacturer’s
instructions. qPCRs were performed in a 20μL reaction mix
containing 20pmol of both forward and reverse primer,
SYBR Premix Ex Taq (Takara Bio Inc., Tokyo, Japan) and
cDNA. Sense and antisense primer sequences were 5 -GAA
AGCCTTCAGTCCCGTGAGGTCCGTT-3  and 5 -CTG
GTGATGCAGGCTGACAATAGTGGGATG-3  for Id2 (271
bp) (Atlas RT-PCR Primer Sequences (Clontech, CA, USA);
5 -CCTGGCACCCAGCACAAT-3  and 5 -GGGCCGGAC
TCGTCATAC-3  for β-actin (145bp) [36]. Samples were
analyzed in duplicate. All reactions were performed in a4 PPAR Research
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Figure 1:FenoﬁbratedownregulatesId2geneexpressioninrats.Leftpanel:relativeamountofmRNAofliverId2,after4-daytreatmentwith
or without fenoﬁbrate in virgin and pregnant rats, measured by semiquantitative RT-PCR. Values were normalized against glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) expression and were represented using arbitrary units. Capital letters correspond to the statistical
comparisons between pregnant and virgin rats receiving the same treatment. Small letters correspond to the statistical comparisons between
rats receiving diﬀerent drug doses. Values not sharing a common letter are signiﬁcantly diﬀerent at P<0.05. Each value represents the
mean ± standard error of ﬁve animals. Right panel: starvation downregulates Id2 gene expression. Relative amount of mRNA of liver Id2
from pregnant rats fed with standard pellet or fasted 24h, measured by semiquantitative RT-PCR. Values were normalized against GAPDH
expression and were represented using arbitrary units. Asterisk represents signiﬁcantly diﬀerent at P<0.05.
LightCycler 5.0 (Roche). Optimal qPCR eﬃciency and
linearity were previously conﬁrmed for each target. Results
for the expression of Id2 mRNA were expressed relative to
t h ec o n t r o lg e n e( β-actin).
2.3. Statistical Analysis. Results were expressed as means ±
S.E. Treatment eﬀects were analyzed by one-way analysis
of variance (ANOVA). When treatment eﬀects were signif-
icantly diﬀerent (P<0.05), means were tested by Tukey
multiple range test. For nonparametric data, the Mann-
Whitney U test was used with diﬀerences between the two
groups analyzed by Student t-test.
3. Results
3.1. Eﬀect of Fenoﬁbrate on Id2 Expression in Pregnant and
Virgin Rats. As shown in Figure 1,h e p a t i cI d 2m R N Al e v e l s
were higher in virgin than in pregnant rats in the absence
of treatment. In nonpregnant rats, hepatic Id2 mRNA levels
were decreased by treatment with fenoﬁbrate, although the
eﬀectathigherdosewasnotsigniﬁcant.PPARαagonisttreat-
ment for 4 days also decreased Id2 mRNA levels in pregnant
rats (Figure 1) independently of the dose used, indicating
that the lower dose was suﬃcient to reduce the expression of
the Id2 gene. These results validate those previously found
by our group when Id2 levels were evaluated using the
samesamplesbymacroarraytechnology(AtlasNylonArrays,
Clontech,BDBiosciences,PaloAlto,CA,USA)(unpublished
results).
3.2. Eﬀect of Fasting on Id2 Expression. It is well known that
several types of fatty acids are PPARα activators [29, 30].
The uptake of fatty acids into the liver as a result of their
mobilization from adipose tissue after fasting would result
in PPARα activation and changes in the expression of its
target genes [31]. Plasma FFA levels in fed rats were 360.84±
22.15μM, signiﬁcantly diﬀerent (P<0.05) from those levels
found in 24h fasted rats: 1,503.90 ± 157.81μM. As shown
in Figure 1, 24h fasting produced a signiﬁcant decrease in
hepatic expression of Id2 in comparison to the rats fed ad
libitum correlating to the increase in circulating fatty acids.
3.3. Requirement for PPARα in Fibrate Regulation of Id2
Expression. Because PPARα has been shown to mediate
several ﬁbrate-inducible responses in the liver, we examined
the dependence of ﬁbrate-induced decreases in Id2 gene reg-
u l a t i o no nP P A R α expression. Wild-type mice and PPARα-
null mice [32] were fed a control diet or the same diet
supplemented with either WY (0.1%) or DEHP (0.6%) for
3 weeks. As shown in Figure 2, when wild-type mice were fed
WY there was a signiﬁcant decrease in the liver expression of
Id2 mRNA, whereas treatment with DEHP, a weaker PPARα
activator, did not change the levels of Id2 mRNA. TreatmentPPAR Research 5
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Figure 2: Downregulation of Id2 gene expression by WY is dependent on PPARα. Wild-type SV129 mice (+/+) or SV129 mice that lack
PPARα (−/−)w e r ef e dac o n t r o ld i e t( Control) or a diet containing WY (0.1%) or DEHP (0.6%) for 3 weeks. Total RNA isolated from liver
was separated by 1.2% agarose, transferred to nylon, and analysed by northern blot using probes for Id2, Ehhadh, and 17βHSD, and GAPDH
as a control. Northern autoradiograms (a) were densitometrically scanned and expression normalized to that of GAPDH (b). Each value
represents the mean ± standard error of three animals. ∗signiﬁcantly diﬀerent from control (P<0.05).
ofPPARα-nullmicewithWYorDEHPresultedinnochange
in Id2 gene expression (Figure 2).
As a positive control of PPARα agonist regulation of gene
expression, we also examined the levels of L-bifunctional
enzyme (Ehhadh) mRNA. As expected [37, 38], Ehhadh
mRNA expression was signiﬁcantly enhanced by WY or
DEHP treatments in wild-type mice but not in PPARα-
null mice (Figure 2). A similar eﬀect was found for 17β-
HSD type IV gene expression (Figure 2), in accordance
with our previously published results [4]. As a negative
control, GAPDH mRNA levels remained constant under all
conditions (Figure 2).
3.4. Eﬀect of Fenoﬁbrate on Id2 Expression in Human Cultured
Cells. Since ﬁbrates depressed Id2 hepatic expression in
rodents in a PPARα mediated manner, we also determined
if Id2 mRNA expression exhibits a similar behaviour in
human cells. Unexpectedly, fenoﬁbrate at 50 and 100μM
increased Id2 mRNA expression after 24 hours of treatment
(Figure 3(a)). A previous report has shown that glucose
could induce Id2 expression in cultured cells [13]. The
EMEM media used here contained 5mM glucose, therefore,
we repeated the experiment in the presence of 20mM
glucose. The results observed in the presence of additional
glucose were similar to those described in Figure 3(a) (data
not shown).
To determine if the activation of Id2 expression is medi-
ated by PPARα in HepG2 cells, the cells were preincubated
with the PPARα antagonist MK-886 [39]. As shown in
Figure 3(b), the eﬀect of fenoﬁbrate was not blocked by
preincubation with MK-886, indicating that the induction6 PPAR Research
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Figure 3: Fenoﬁbrate upregulates Id2 gene expression in HepG2 cells. Panel (a) human hepatocarcinoma cells treated with diﬀerent
concentrations of fenoﬁbrate (0, 10, 50, or 100μM) for 2, 6, or 24 hours. Relative Id2 mRNA levels were measured by real-time PCR,
normalized to β-actin levels and expressed in relative units to control. Values for Id2 mRNA are expressed as mean ± SD (n = 3). Panel (b)
HepG2 cells were preincubated with the PPARα antagonist MK-886 (10μM) where indicated and treated with diﬀerent concentrations of
fenoﬁbrate (0 or 50μM) for 24 hours.
was independent of PPARα. Instead, the PPARα antagonist
showed an additive eﬀect with fenoﬁbrate on Id2 mRNA
expression (Figure 3(b)). Glutathione S-transferase pi 1
(Gstp1), which expression has been recently shown to be
modiﬁed by PPARα activators [40], was also measured.
Fenoﬁbrate increased Gstp1 expression (1.7-fold induction
versus control without drug), whereas MK-886 abolished the
eﬀect of fenoﬁbrate on HepG2 cells.
A recent report showed that Id2 expression could be
inﬂuenced by circadian rhythm [16], and it has been previ-
ously established that serum is able to induce circadian gene
expression [41, 42]. Therefore, an additional experiment was
carried out with MK886 and fenoﬁbrate, in which the cells
were cultured in serum-free medium for 36 hours instead
of 24 hours. Similar results to those observed in Figure 3(b)
were obtained when the serum was substituted with BSA, 36
hours before the treatment with the drugs (data not shown).
4. Discussion
In this study, we found that fenoﬁbrate treatment repressed
liver Id2 mRNA expression both in pregnant and virgin
rats. These ﬁndings agree with those of Yamazaki et al.
[43] using cDNA microarrays from mice after 2 or 3
days oral administration of fenoﬁbrate (100mg/kg) or WY
(30mg/kg), and are consistent with those reported by Wong
and Gill [44] after 1.0% DEHP in the diet for 13 weeks as
studied by microarrays.
Glucocorticoids, whose circulating levels are augmented
during pregnancy [45], have been described as repressors
of Id2 expression in cells [46]. In agreement with this,
basal levels of Id2 mRNA in pregnant rats were lower
than in unmated rats, the diﬀerence being also observed
after fenoﬁbrate treatment. These ﬁndings emphasize the
downregulatory eﬀect of PPARα agonists, independent of
whether Id2 mRNA levels are low, as in gestation, or elevated
as in nonpregnant rats.
Fastingproducesmobilizationoffattyacidsfromadipose
tissue. Fatty acids are natural activators of PPARα [29, 31,
47].Therefore,thearrivaloffattyacidsintheliverasresultof
starvation, led to a signiﬁcant decrease in hepatic expression
of Id2. This ﬁnding reinforces the idea that PPARα activation
produces a decrease in Id2 mRNA expression in liver.
Id2-null mice exhibit a decrease in adipose tissue and
liver fat deposition compared to wild-type mice [16].
Consistent with that, Id2-overexpressing adipocytes show
increased capacity for morphological diﬀerentiation and
lipid accumulation [15]. In contrast, we found that PPARα
activators decrease Id2 gene expression under the same
conditions as we had previously reported an accumulation
of lipids in the liver. Thus, hepatic triglyceride content
in fasted rats was higher in comparison to fed condition
[48], and it was also augmented in nonpregnant fenoﬁbrate
treated rats (in comparison to nontreated unmated rats)
[24]. Nevertheless, although Id2 mRNA expression was also
modiﬁed by fenoﬁbrate in late gestation, hepatic triglyceride
content was not aﬀected by the drug in pregnant rats [24].
Since it has been reported that Id2 inhibits lipogenesis by
interferingwiththetranscriptionalactivityofSREBP1catthe
fatty acid synthase (FAS) promoter [19], our results might
reﬂect an increased lipogenesis along with an Id2 repression.
However, the hepatic expression of FAS was not signiﬁcantly
changed by fenoﬁbrate in virgin or in pregnant rats [24], and
24h fasting instead decreased FAS expression in pregnant
rats (unpublished results).
We found a decrease in the expression of Id2 in mice
treated with WY-14,643, yet this eﬀect was not seen withPPAR Research 7
DEHP, indicating that the eﬀect depends on PPARα activator
potency. In the case of mice that lacked a functional form
of PPARα,d i ﬀerences were not observed after the diﬀerent
treatments, suggesting that it was an eﬀect mediated by
PPARα. This ﬁnding is in agreement with that one recently
described by el Azzouzi et al. [49] in murine cardiomyocyte
cells using cDNA microarrays. One of gene listed by these
authors to be speciﬁcally downregulated by WY was Id2.
However, neither GW-5015160 (a PPARβ/δ agonist) nor
rosiglitazone (a PPARγ agonist) produced any change. Thus,
it can be assumed that ﬁbrates aﬀect Id2 gene expression
through PPARα.
The decrease found in the expression of Id2 in mice by
the potent PPARα activator WY agrees with the reduction
observed in rats treated with fenoﬁbrate. Since, it appears
that both STAT3 and C/EBPβ are involved in regulation of
Id2 [50, 51], and it is known that PPARα activation interferes
with signalling pathways dependent on C/EBP and STAT
[52], we hypothesize that PPARα may negatively regulate Id2
through inhibition of STAT3 or C/EBP.
In contrast to rodents, the negative eﬀect of ﬁbrates
on Id2 gene expression was not observed in human cells.
Fenoﬁbrate enhanced Id2 mRNA levels in these cells after
a 24h incubation. Moreover, since Grønning et al. [13]
have shown in murine macrophages that glucose induces
increases in protein levels of this transcriptional repressor,
we studied the eﬀect of ﬁbrates both at low glucose and high
glucose and found a similar fenoﬁbrate-inducing eﬀect on
Id2 mRNA expression. The eﬀectof fenoﬁbratewasobserved
after 24-h incubation, suggesting that regulation of Id2
expression by PPAR might occur by an indirect mechanism
[53]. Nevertheless, several PPARα target genes [54]w e r e
also induced after 24-hour administration of ﬁbrates but
not earlier. Therefore, we studied the eﬀect of MK-886, an
antagonist of PPARα and found that fenoﬁbrate-induced
increases in Id2 mRNA expression were not abolished by
preincubation with MK-886, conﬁrming that the eﬀect
was not mediated by PPARα. In accordance with this
ﬁnding, TZD, which also modulate Id2 mRNA levels in
cultured human cells, use a PPARγ-independent mechanism
[10]. Fenoﬁbrate and MK-886 functioned synergistically to
stimulate Id2 expression. The MK-886-induced increase in
Id2 mRNA expression could be caused by two mechanisms:
(i) speciﬁc inactivation of PPARα; (ii) other pathways, such
as inhibition of leukotriene biosynthesis [39]. Therefore, it is
assumedthatfenoﬁbrate-inducedincreasesinId2expression
occurbyaPPARα-independentmechanism.Howfenoﬁbrate
increases Id2 expression in HepG2 cells remains elusive.
Finally, Id proteins are HLH transcription factors that
participateindevelopment,cellcyclecontrol,diﬀerentiation,
and tumorigenesis [17]. However, the role of Id2 protein in
the mechanism of action of ﬁbrates has not been elucidated.
Altogether, these ﬁndings conﬁrm that Id2 gene expression
is responsive to PPARα activators (ﬁbrates and possibly fatty
acids). However, as reported for other genes (apoA-I, apoA-
V) ([2] and references therein), the eﬀects are opposite
in rodents versus humans. Since peroxisome proliferators
function as hepatocarcinogenic agents in rodents, but not
in humans [55], and considering the role of Id2 protein
in cell proliferation and cancer [17], we speculate that the
diﬀerential response to ﬁbrate exposure might be related to
the diﬀerences in liver tumorigenesis between species.
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